- Home
- GERN vs GHRS Comparison
GERN vs GHRS Comparison
Compare GERN & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- GHRS
- Stock Information
- Founded
- GERN 1990
- GHRS 2018
- Country
- GERN United States
- GHRS Ireland
- Employees
- GERN N/A
- GHRS N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- GERN Health Care
- GHRS Health Care
- Exchange
- GERN Nasdaq
- GHRS Nasdaq
- Market Cap
- GERN 853.5M
- GHRS 849.8M
- IPO Year
- GERN 1996
- GHRS 2021
- Fundamental
- Price
- GERN $1.51
- GHRS $12.31
- Analyst Decision
- GERN Buy
- GHRS Strong Buy
- Analyst Count
- GERN 7
- GHRS 8
- Target Price
- GERN $4.17
- GHRS $30.63
- AVG Volume (30 Days)
- GERN 10.9M
- GHRS 187.6K
- Earning Date
- GERN 08-07-2025
- GHRS 05-08-2025
- Dividend Yield
- GERN N/A
- GHRS N/A
- EPS Growth
- GERN N/A
- GHRS N/A
- EPS
- GERN N/A
- GHRS N/A
- Revenue
- GERN $116,293,000.00
- GHRS N/A
- Revenue This Year
- GERN $160.12
- GHRS N/A
- Revenue Next Year
- GERN $55.01
- GHRS N/A
- P/E Ratio
- GERN N/A
- GHRS N/A
- Revenue Growth
- GERN 22264.04
- GHRS N/A
- 52 Week Low
- GERN $1.17
- GHRS $6.00
- 52 Week High
- GERN $5.06
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- GERN 51.36
- GHRS 52.37
- Support Level
- GERN $1.42
- GHRS $12.43
- Resistance Level
- GERN $1.58
- GHRS $13.15
- Average True Range (ATR)
- GERN 0.10
- GHRS 0.99
- MACD
- GERN -0.01
- GHRS -0.14
- Stochastic Oscillator
- GERN 40.00
- GHRS 41.03
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.